|Mr. Michael R. Martin||Co-Founder & COO||350.57k||N/A||N/A|
|Mr. Dennis Bourgeault CPA, C.A.||CFO & Sec.||329.19k||N/A||N/A|
|Dr. Robert B. Huizinga M.Sc., Ph.D., RN NNC, MSc(Epi), CNeph(C)||Exec. VP of Corp. Devel.||436.26k||N/A||N/A|
|Dr. Richard M. Glickman||Advisor||887.25k||N/A||1958|
|Dr. Neil Solomons M.D.||Chief Medical Officer||471.21k||N/A||N/A|
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of June 25, 2019 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 8.